You’ve probably seen the same frustrating pattern I have. You search for BPC-157 dosage information and get either wildly specific numbers with zero context, or the unhelpful “everyone is different, talk to your doctor” brush-off.
Here’s the thing. Most doctors have never heard of BPC-157. And the people actually using it are piecing together information from research papers, forums, and trial and error. That’s not ideal, but it’s the reality.
So let’s talk about what doses people are actually using, what the research shows, and where the gaps in our knowledge really are.
What the Research Actually Tells Us (And Doesn’t)
First, some important context. BPC-157 has been studied extensively, but almost entirely in animals. We’re talking rats, mice, and occasionally rabbits. Human clinical trials? They exist, but they’re limited and mostly focused on inflammatory bowel conditions using oral formulations.
The honest answer is that we don’t have FDA-approved human dosing guidelines because BPC-157 isn’t an approved drug. What we have instead is a combination of rodent study data that researchers have attempted to scale to human equivalents, and real-world reports from people who’ve used it.
Neither source is perfect. But together, they give us a reasonable starting point.
How Researchers Convert Animal Doses to Human Estimates
In rodent studies, BPC-157 is typically administered at doses between 10 mcg/kg and 50 mcg/kg of body weight. Some studies go higher, up to 100 mcg/kg or more, but the 10-50 mcg/kg range is most common.
Converting animal doses to human equivalents isn’t straightforward multiplication. Researchers use something called allometric scaling, which accounts for differences in metabolism between species. A commonly used conversion factor suggests you divide the rat dose by about 6.2 to get a human equivalent.
Using this math, a 10 mcg/kg rat dose translates to roughly 1.6 mcg/kg for humans. For a 180-pound (82 kg) person, that works out to approximately 130 mcg per day on the low end.
At the higher end of the rodent range (50 mcg/kg), the human equivalent would be around 650 mcg daily for that same person.
This gives us a theoretical window of roughly 150-700 mcg per day, assuming the scaling models are accurate. That’s a big assumption, but it’s the foundation most dosing discussions build from.
What People Are Actually Taking
Now let’s look at what’s happening outside the lab.
Based on user reports across forums, communities, and anecdotal accounts, most people using BPC-157 for injury recovery or gut issues fall into a few common patterns.
The conservative approach involves 200-300 mcg once or twice daily. People in this camp often cite wanting to “start low and see what happens.” Total daily dose: 200-600 mcg.
The moderate approach sits around 250-500 mcg twice daily, totaling 500-1000 mcg per day. This seems to be the most commonly reported range for people targeting tendon, ligament, or muscle injuries.
The aggressive approach involves 500 mcg or more, two to three times daily. Some users report taking 1500 mcg or higher per day, particularly for stubborn injuries. This exceeds most calculated human-equivalent doses from rodent studies.
What we don’t know yet is whether higher doses actually produce better results, or if there’s a ceiling effect where additional BPC-157 stops providing additional benefit. The animal data doesn’t clearly answer this, and we don’t have controlled human studies to fill the gap.
Injection vs. Oral: Does the Route Change the Dose?
This matters more than people realize.
Subcutaneous injection delivers BPC-157 directly into tissue, bypassing the digestive system. Bioavailability is presumably much higher, though exact numbers for BPC-157 specifically haven’t been established in humans.
Oral BPC-157 has to survive stomach acid and intestinal absorption. The peptide is reportedly stable in gastric juice, which is part of why researchers have studied it for gut conditions. But how much actually reaches systemic circulation when swallowed? That’s unclear.
Some users take higher oral doses to compensate, sometimes 500 mcg or more. Others argue that for gut-specific issues, oral administration makes more sense because you want the peptide working locally in the digestive tract.
The honest answer is we don’t have good comparative data on oral vs. injectable bioavailability in humans. If you’re targeting a gut issue, oral might make sense. For a knee tendon or shoulder injury, most users opt for injection near the injury site or subcutaneously in general.
Local vs. Systemic Injection: Does Location Matter?
You’ll see debates about whether to inject BPC-157 close to an injury or whether it works just as well injected anywhere subcutaneously.
The theory behind local injection is straightforward: put the peptide near the damaged tissue so it can work directly on the area. Some users swear by this approach, injecting within an inch or two of the injury site.
Others inject wherever is convenient, typically in abdominal fat, and report similar results. The argument here is that BPC-157 is small enough to distribute systemically and will find its way to damaged tissue regardless of injection location.
Animal studies have shown benefits from both systemic and local administration. What we don’t have is comparative human data showing one approach is definitively superior.
Practically speaking, many people inject locally when the injury is easily accessible (like an Achilles tendon or elbow) and systemically when it’s not (like a deep hip issue).
How Long Do People Run BPC-157?
Duration varies almost as much as dosing.
Short protocols run 2-4 weeks. Some users report noticeable improvement in minor injuries within this window and stop once symptoms resolve.
Standard protocols last 4-8 weeks. This is probably the most common timeframe for moderate injuries. Many users follow patterns like “4 weeks on, 2 weeks off, reassess.”
Extended protocols go beyond 8 weeks, sometimes 12 weeks or longer for chronic issues. There’s limited data on long-term use, so people running extended protocols are essentially experimenting on themselves.
What we don’t know is whether there are diminishing returns over time, whether breaks are necessary, or if extended use carries risks we haven’t identified yet. The rodent studies typically run a few weeks at most.
The Purity Problem Nobody Talks About Enough
Here’s where I have to be straight with you. Dosing discussions assume you’re getting what the label says. That’s not always true.
BPC-157 is sold as a research chemical, not a regulated pharmaceutical. Quality control varies dramatically between suppliers. Some products have been tested and found to contain less peptide than advertised, different peptides, or contaminants.
If you’re taking what you think is 500 mcg but it’s actually 300 mcg, your real-world experience won’t match what others report at the same nominal dose. If there are impurities, you’re introducing variables that have nothing to do with BPC-157 itself.
Third-party testing through independent labs is the only way to verify what’s actually in a product. Some suppliers publish certificates of analysis. Whether those certificates are accurate and current is another question.
This isn’t meant to scare you off. It’s just reality. The dosing ranges people report are only meaningful if the products are legitimate.
Putting It Together: A Reasonable Starting Framework
If I had to summarize the landscape, it would look like this.
Most people start somewhere between 250-500 mcg per day, often split into two doses. Those using it for injury recovery typically inject subcutaneously, either near the injury or in abdominal fat. Protocols commonly run 4-8 weeks.
Some people use more. Some use less. Individual responses vary, and without controlled studies, we can’t say definitively what’s optimal.
What makes sense for you depends on what you’re trying to address, your comfort level with experimentation, and your ability to source quality products. If you’re dealing with something serious or complicated, finding a practitioner who actually knows peptides (they exist, though they’re not common) is worth the effort. Not because I’m passing the buck, but because having someone monitor your situation and adjust based on your response beats guessing alone.
The research on BPC-157 is genuinely interesting. The gap between that research and clear human dosing guidelines is genuinely frustrating. What we have right now is imperfect information and a community of people trying to figure it out in real time.
At least now you know what they’re actually doing.